Knight Capital Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Knight Capital Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$3.85M	Buy	+48,100	New	+$3.54M	0.07%	242

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Knight Capital Group's VRTX Position: Q2 2013 in Review

Knight Capital Group opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2013: 4,708 shares worth $376K. The stake represents 0.01% of the portfolio and ranks #1993 among its holdings.

376 funds tracked by Wall St. Rank hold VRTX as of Q2 2013.

Knight Capital Group held 4,708 shares of Vertex Pharmaceuticals worth $376K as of Q2 2013.
Vertex Pharmaceuticals was a new Knight Capital Group position in Q2 2013.
Vertex Pharmaceuticals made up 0.01% of Knight Capital Group's portfolio in Q2 2013, its #1993 holding.
376 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.